Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

12.37
-0.8700-6.57%
Post-market: 12.35-0.0200-0.16%19:58 EDT
Volume:3.74M
Turnover:46.94M
Market Cap:1.46B
PE:-3.25
High:13.16
Open:13.12
Low:12.12
Close:13.24
52wk High:28.25
52wk Low:5.90
Shares:118.13M
Float Shares:112.00M
Volume Ratio:0.91
T/O Rate:3.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.18
PE(LYR):-3.25

Loading ...

Earnings Flash (NTLA) Intellia Therapeutics Posts Q4 Net Loss $0.83 a Share, vs. FactSet Est of $0.95 Loss

MT Newswires Live
·
Feb 26

Intellia Therapeutics Q4 Net Income USD -95.786 Million

Reuters
·
Feb 26

Stock Track | Intellia Therapeutics Soars 5.96% in Pre-Market on Strong Q4 Earnings Beat and Positive Pipeline Updates

Stock Track
·
Feb 26

Intellia posts Q4 collaboration revenue of USD 23.0 million (+78.6%)

Reuters
·
Feb 26

Intellia Therapeutics Q4 EPS $(0.83) Beats $(0.96) Estimate, Sales $23.017M Beat $12.812M Estimate

Benzinga
·
Feb 26

Intellia Therapeutics Q4 Basic EPS USD -0.83

THOMSON REUTERS
·
Feb 26

Intellia Therapeutics Q4 Collaboration Revenue USD 23.017 Million

THOMSON REUTERS
·
Feb 26

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

GlobeNewswire
·
Feb 26

Intellia’s New Cell Therapy Alliances Add Optionality To Growth Story

Simply Wall St.
·
Feb 25

Intellia Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Feb 24

Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates

Reuters
·
Feb 19

Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors

Simply Wall St.
·
Feb 18

Intellia Therapeutics reports inducment grants

TIPRANKS
·
Feb 06

Intellia Therapeutics Awards Inducement Grants to New Employees

Reuters
·
Feb 06

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 06

FDA Clears Intellia Phase 3 ATTRv PN Trial Lifting Key Overhang

Simply Wall St.
·
Feb 04

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial

Simply Wall St.
·
Feb 01

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis

TIPRANKS
·
Jan 31

Is Intellia Therapeutics (NTLA) Now Pricing In Too Much After Its Recent Surge

Simply Wall St.
·
Jan 29

Intellia Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 29